BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38010569)

  • 1. Effectiveness of venetoclax and azacytidine against myeloid/natural killer cell precursor acute leukemia.
    Shiomi I; Nakako S; Nakane T; Ogawa Y; Araki T; Fujitani Y; Yamamura R; Hino M; Nakamae H
    Int J Hematol; 2024 Jan; 119(1):88-92. PubMed ID: 38010569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five Chinese pediatric patients with leukemias possibly arising from immature natural killer cells: clinical features and courses.
    Guan XQ; Xu L; Ke ZY; Huang LB; Zhang XL; Zhang YC; Luo XQ
    Pediatr Hematol Oncol; 2011 Apr; 28(3):187-93. PubMed ID: 21271777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
    Pasvolsky O; Shimony S; Ram R; Shimoni A; Shargian L; Avni B; Wolach O; Shochat T; Yerushalmi R; Amit O; Raanani P; Yeshurun M
    Ann Hematol; 2022 Feb; 101(2):379-387. PubMed ID: 34628534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
    Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
    Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
    [No Abstract]   [Full Text] [Related]  

  • 5. A child case of CD34+, CD33-, HLA-DR-, CD7+, CD56+ stem cell leukemia with thymic involvement.
    Nagata T; Higashigawa M; Nagai M; Zhang XL; Azuma E; Komada Y; Sakurai M
    Leuk Res; 1996; 20(11-12):983-5. PubMed ID: 9009257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside.
    Handa H; Motohashi S; Isozumi K; Komatsumoto S; Nara M
    Acta Haematol; 2002; 108(1):47-52. PubMed ID: 12145468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity.
    Suzuki R; Yamamoto K; Seto M; Kagami Y; Ogura M; Yatabe Y; Suchi T; Kodera Y; Morishima Y; Takahashi T; Saito H; Ueda R; Nakamura S
    Blood; 1997 Sep; 90(6):2417-28. PubMed ID: 9310493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Venetoclax and azacitidine induced cytogenetic response in an elderly patient with IDH2- and DNMT3A-mutated refractory acute myeloid leukemia].
    Kunisada K; Matsuoka A; Yoshida S; Taoka T
    Rinsho Ketsueki; 2022; 63(12):1621-1625. PubMed ID: 36653133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haploidentical Natural Killer Cell Therapy as an Adjunct to Stem Cell Transplantation for Treatment of Refractory Acute Myeloid Leukemia.
    Kulkarni U; Arunachalam AK; Palani HK; Nair RR; Balasundaram N; Venkatraman A; Korula A; Selvarajan S; Lionel S; Balasubramanian P; Maddali M; Abraham A; George B; Mathews V
    Cell Transplant; 2023; 32():9636897231198178. PubMed ID: 37706453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Venetoclax and Azacitidine in Acute Myeloid Leukemia Compared to Azacitidine Monotherapy: Real-World Experience.
    Baba Y; Hida N; Sambe T; Abe M; Kabasawa N; Sakai H; Yoshimura K; Fukuda T
    Anticancer Res; 2024 May; 44(5):2003-2007. PubMed ID: 38677735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of a child with myeloid/NK cell precursor acute leukemia with L-asparaginase and unrelated cord blood transplantation.
    Tezuka K; Nakayama H; Honda K; Suzumiya J; Oshima K; Kitoh T; Ishii E
    Int J Hematol; 2002 Feb; 75(2):201-6. PubMed ID: 11939270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
    Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis.
    Li X; Suh HS; Lachaine J; Schuh AC; Pratz K; Betts KA; Song J; Dua A; Bui CN
    Value Health; 2023 Dec; 26(12):1689-1696. PubMed ID: 37741447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy.
    Winters AC; Bosma G; Abbott D; Minhajuddin M; Jordan C; Pollyea DA; Gutman JA
    Transplant Cell Ther; 2022 Oct; 28(10):694.e1-694.e9. PubMed ID: 35902048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with azacitidine, etoposide, and cytarabine in the treatment of elderly acute myeloid leukemia patients: A single center experience.
    Onec B; Okutan H; Albayrak M; Can ES; Aslan V; Koluman BU; Kosemehmetoglu OS; Albayrak A
    J Cancer Res Ther; 2018; 14(5):1105-1111. PubMed ID: 30197357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of 7 cases of pediatric acute myeloid leukemia with DEK-NUP214 fusion gene].
    Li XL; Liu LP; Wan Y; Liu F; Chen X; Ren YY; Ruan M; Guo Y; Zhu XF; Yang WY
    Zhonghua Er Ke Za Zhi; 2023 Apr; 61(4):357-362. PubMed ID: 37011983
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
    Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD
    Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial.
    Wang H; Mao L; Yang M; Qian P; Lu H; Tong H; Xie W; Zhou D; Huang X; Wang Y; Xu G; Lu Y; Wei J; Mai W; Ye X; Meng H; Shen Y; Huang J; Yu W; Sun J; Sheng J; Yan X; Jin J; Zhu HH
    Lancet Haematol; 2022 Jun; 9(6):e415-e424. PubMed ID: 35512726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.
    Maurillo L; Buccisano F; Spagnoli A; Voso MT; Fianchi L; Papayannidis C; Gaidano GL; Breccia M; Musto P; De Bellis E; Del Principe MI; Lunghi M; Lessi F; Martinelli G; Venditti A
    Ann Hematol; 2018 Oct; 97(10):1767-1774. PubMed ID: 29947973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report.
    Wang L; Lin N
    Medicine (Baltimore); 2021 Feb; 100(6):e24703. PubMed ID: 33578607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.